Table 2.
Associations between CDCA5 protein expression and clinicopathological factors.
| Factors | N = 118 | Negative (n = 68) | Positive (n = 50) | Pa |
|---|---|---|---|---|
| Gender | 0.937 | |||
| Male | 76 | 44 (64.7%) | 32 (64.0%) | |
| Female | 42 | 24 (35.3%) | 18 (36.0%) | |
| Age | 0.397 | |||
| ≤60 years | 56 | 30 (44.1%) | 26 (52.0%) | |
| >60 years | 62 | 38 (55.9%) | 24 (48.0%) | |
| T stage | 0.007 | |||
| T1-2 | 23 | 19 (27.9%) | 4 (8.0%) | |
| T3-4 | 95 | 49 (72.1%) | 46 (92.0%) | |
| N stage | 0.018 | |||
| N0 | 69 | 46 (67.6%) | 23 (46.0%) | |
| N+ | 49 | 22 (32.4%) | 27 (54.0%) | |
| Differentiation | 0.604 | |||
| G1 | 46 | 29 (42.6%) | 17 (34.0%) | |
| G2 | 60 | 33 (48.5%) | 27 (54.0%) | |
| G3 | 12 | 6 (8.9%) | 6 (12.0%) | |
| Location | 0.397 | |||
| Upper | 5 | 2 (2.9%) | 3 (6.0%) | |
| Middle | 30 | 15 (22.1%) | 15 (30.0%) | |
| Lower | 83 | 51 (75.0%) | 32 (64.0%) | |
| TNM stage | 0.008 | |||
| I–II | 73 | 49 (72.1%) | 24 (48.0%) | |
| III–IV | 45 | 19 (27.9%) | 26 (52.0%) |
a
Based on χ2 test.